Evidenced closes $24M Fund I to back health tech riding regulation
What's the deal? EvidencedDealroom has a profile for this one. Try Dealroom →, a US venture firm, has closed its debut fund at $24 million to invest in health tech startups. Backers include the Rockefeller Foundation, RockCreek Group, and Colibri Equity VenturesDealroom has a profile for this one. Try Dealroom →, alongside individual limited partners drawn from government, healthcare delivery, technology, and the payer ecosystem.
The thesis: Most investors treat regulation as a hazard to hedge against. Evidenced argues the opposite — that certain policy decisions open or create entire markets, and startups that catch those tailwinds grow faster while carrying less risk.
Why now? The firm points to current openings such as the Centers for Medicare and Medicaid Services ACCESS model and the Rural Health Transformation Fund as examples of policy driving demand.
Who's behind it? Evidenced was co-founded in 2022 by Sean Glass and Bryan Sivak. Glass co-founded and scaled women's healthcare company Advantia Health to roughly $100 million in revenue and earlier founded Higher OneDealroom has a profile for this one. Try Dealroom →, which went public in 2010. Sivak was chief technology officer at the US Department of Health and Human Services and held roles at Kaiser Permanente VenturesDealroom has a profile for this one. Try Dealroom → and Centene.
What's the endgame? The portfolio spans community health infrastructure, behavioural health, aging-in-place, advance care planning, and neurodiverse therapeutics. Holdings include Ilant Health, a value-based obesity care company that raised a $15 million Series A this cycle, and Parento, a paid parental leave insurer for employers.
Other investments include Accompany Health, Fabric Health, Floreo, Here Now Health, IMPaCT Care, Journey Clinical, Jukebox Health, Koda Health, Photon Health, and Truentity.
The signal: A dedicated fund built around reading policy as a market catalyst is a distinct bet in health tech, where regulation usually reads as friction. Glass's operating background in women's health also positions Evidenced in a segment that draws relatively few investors with hands-on experience.
Read more: FemTech Insider
Image credit: USDAgov
